Secukinumab (anti-IL-17A)

Synonyms: AIN457

Catalog No.A2025 Purity:99.82%

Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

Click to purchase the isotype control of Secukinumab (anti-IL-17A)

Selleck's Secukinumab (anti-IL-17A) has been cited by 2 publications

Purity & Quality Control

Batch: A202501 Purity: 99.82% Protein concentration: 5.00mg/ml Endotoxin Level: <1EU/mg

99.82

Choose Selective Interleukins Inhibitors

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

In Vitro
In vitro	Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system.^[1]
Cell Research:	MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor.

In Vitro

In vitro

Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system.^[1]

Cell Research:

MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor.

In Vivo
In vivo	Secukinumab administration significantly attenuates AAV8-IRF8 mediated recruitment of neutrophils, also downregulates the autophagy level and inhibits the release of either autophagy-dependent or independent chemokines in vivo.^[2]
Animal Research	Animal Models: C57BL/6 mice, IRF8 FLOX mice (C57BL/6J background) Dosages: 200 μg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/34400126/

References
[1] Sun R, et al. Signal Transduct Target Ther. 2022 Mar 18;7(1):80. [2] Shi G, et al. Biochem Pharmacol. 2021 Oct;192:114728.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1229022-83-6
Isotype	Human IgG1
Source	Human
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.